The FDA’s approval of Eli Lilly’s oral weight-loss drug Foundayo has set up a direct competitive push from Novo Nordisk to defend oral Wegovy. Novo highlighted differences in weight-loss outcomes, pointing to analyses comparing the oral Wegovy pill to Foundayo and noting dosing requirements. Analysts framed the launch as an early test of how quickly patients adopt the newer oral option versus existing oral demand drivers. Novo said it is preparing data presentations for simulated comparisons, while acknowledging that no head-to-head trial has been run. The episode matters for biotech and pharma planning because oral GLP-1s are shifting the competitive center of gravity toward convenience, pricing negotiations, and differentiating label claims supported by the next round of comparative datasets.